GlassScriptPhysician profile
Avie A Grunspan
NPI 1881695542
$3,141.80
in general payments reported to CMS, 2019-2025
22 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $130 · 2021: $184 · 2022: $525 · 2023: $829 · 2024: $687 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475 · Consulting Fee: $200 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,475.41 |
| Consulting Fee | $200.00 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $1,235.06 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $494.04 | 2019-2024 | Xywav |
| Avadel Cns Pharmaceuticals, LLC | $319.35 | 2023-2025 | Lumryz |
| Regeneron Healthcare Solutions, INC. | $162.82 | 2019 | |
| Fisher & Paykel Healthcare INC | $160.88 | 2023-2024 | Fisher & Paykel Healthcare |
| Axsome Therapeutics, INC. | $121.60 | 2023-2024 | Sunosi |
| Avadel Specialty Pharmaceuticals, LLC | $112.93 | 2019 | |
| Idorsia Pharmaceuticals US INC | $73.48 | 2023-2024 | Quviviq |
| Philips North America LLC | $61.02 | 2019-2023 | |
| Resmed Corp | $57.75 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $51.16 | 2019 | |
| Almatica Pharma LLC | $40.46 | 2023 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $38.44 | 2023-2024 | Hetlioz |
| Inspire Medical Systems, INC. | $29.92 | 2023 | Inspire |
| Eisai INC. | $28.85 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $28.57 | 2022-2023 | Belsomra |
| Azurity Pharmaceuticals, INC. | $27.78 | 2023-2024 | Horizant, Horizant |
| Arbor Pharmaceuticals, INC. | $23.23 | 2019-2021 | |
| Itamar Medical INC | $21.94 | 2022 | |
| Sobi, INC | $20.46 | 2019 | |
| Baxter Healthcare | $17.35 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Ucb, INC. | $14.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avie Grunspan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.